Much of what we know about the long-term outcomes of people with chronic myelogenous leukemia comes from clinical studies. Such studies provide important information about how well a person with CML can do over the longer term. But one of their limitations is that studies are selectiv
It’s well known that the introduction of tyrosine kinase inhibitors (TKIs, such as Gleevec, Sprycel, Tasigna and Bosulif) have significantly prolonged survival in people with chronic myelogenous leukemia. Where once a CML diagnosis meant an expected survival of only a few years, survi
Before the second-generation TKIs (Sprycel, Tasigna, Bosulif) became available, the best option for people with an inadequate response to Gleevec was to give more Gleevec. So many studies used twice the usual dose (or 800 mg per day).
A new study has looked at the proportion of people with CML who achieve the key treatment milestones, which represent the optimal response to a medication at different time points (Jain and colleagues. Br J Haematol 2016;173:114-126). These milestones are developed by research groups
Gleevec has been the cornerstone of CML treatment for the past 15 years. However, the introduction of a generic formulation (imatinib) has made patients and physicians uncertain about the medications that are being used, according to The CML Advocates Network, a network of CML patient
TKI (tyrosine kinase inhibitor) therapy established a new standard for what medications could achieve in the treatment of CML (and set the bar for all cancer therapies). With TKIs, the goal posts shifted, but what constitutes a success has continued to evolve over time. The most recen
After being diagnosed with chronic myelogenous leukemia, you and your doctor will need to make some decisions about the treatments you’ll need to keep your disease under control. The following are some of the most important questions about CML medications and how medical research has
The development of Gleevec in 2001 revolutionized the treatment of CML. But the medication – although highly effective – won’t work in everyone, and some people may develop resistance to the drug. One reason for resistance is mutations, and over 80 different mutations have now been de